The emerging role of thalidomide therapy in HIV-infected patients

Patrick Haslett, Victoria H. Freedman, Gilla Kaplan

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Thalidomide is a potent immune response-modifying drug; among its known modes of action is the inhibition of the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha, or 'cachectin'). Clinical studies have shown that thalidomide may ameliorate AIDS-associated weight loss. In addition, clinical evidence indicates a role for thalidomide in the treatment of HIV-associated aphthous ulceration. However, toxicities from thalidomide therapy are more common in patients infected with HIV than in uninfected persons, and patients must be monitored carefully to avoid the drug's well-known teratogenic effects.

Original languageEnglish (US)
Pages (from-to)393-398+405-406
JournalInfections in Medicine
Issue number5
StatePublished - May 1 1997
Externally publishedYes


  • AIDS wasting syndrome
  • Aphthous ulcers
  • Immunomodulation
  • Thalidomide
  • Tumor necrosis factor-alpha

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'The emerging role of thalidomide therapy in HIV-infected patients'. Together they form a unique fingerprint.

Cite this